Agonist News and Research

RSS
Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

High-resolution structures of SSTR5 reveal key interactions with neuropeptide and drug agonists

High-resolution structures of SSTR5 reveal key interactions with neuropeptide and drug agonists

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Genetic discovery reveals key to inflammatory diseases

Genetic discovery reveals key to inflammatory diseases

Curcumin nanoparticles show promise in treating neurodegenerative diseases

Curcumin nanoparticles show promise in treating neurodegenerative diseases

Weight loss drug may change how obese people perceive taste

Weight loss drug may change how obese people perceive taste

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

SELECT trial shows semaglutide reduces kidney decline in obese patients

SELECT trial shows semaglutide reduces kidney decline in obese patients

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

Study reveals low adoption of recommended smart inhaler therapy for asthma

Study reveals low adoption of recommended smart inhaler therapy for asthma

High price of popular diabetes drugs deprives low-income people of effective treatment

High price of popular diabetes drugs deprives low-income people of effective treatment

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Monell study uncovers dual role of mammalian sweet taste receptor in regulating blood sugar levels

Monell study uncovers dual role of mammalian sweet taste receptor in regulating blood sugar levels

Research highlights complexity of xylazine and fentanyl combination in overdose cases

Research highlights complexity of xylazine and fentanyl combination in overdose cases

Technology alone insufficient for meaningful weight loss in obesity, study shows

Technology alone insufficient for meaningful weight loss in obesity, study shows

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.